All Blogs
Aug 07, 2026
The Emergence of Oral PCSK9 Inhibitors: A Transformative Innovation in Lipid Management
Summary For nearly a decade, PCSK9 inhibitors have been highly effective at lowering LDL cholesterol, but their growth has been limited by the need for injections. The U.S. FDA approval of Merck’s LIPFENDRA (enlicitide) changes that by introducing the first oral PCSK9 inhibitor, marking a major shift from ne...
Read More...
Aug 06, 2026
Rongtao Medical Receives Prestigious Bonded Repair Authorization for Ultrasound in China; NIPRO Introduces ELISIO™-HX Expanded Hemodialysis System to U.S. Market Following FDA Clearance; Lyric Health Unveils Asynchronous Care Solution for Smarter, Connected Virtual Care; New England Biolab® Strengthens Cell-Free RNA Workflow with Monarch® Mag Cell-free RNA Extraction Kit; Aqua Medical Advances Type 2 Diabetes Research with First U.S. Patient Treated at UNC Health; MediView XR90™ Holographic Surgical Navigation System Debuts in Florida at Cleveland Clinic Weston Hospital
Rongtao Medical Wins Bonded Repair Approval as One of the First in China for Ultrasound On 05 August 2026, Rongtao Medical received regulatory approval to conduct bonded repair services for imported ultrasound systems, becoming one of the earliest companies in China to obtain this qualification. The approv...
Read More...
Aug 05, 2026
The Role of Digital Twins in Medical Device Development and Testing
Medical device innovation has always been a race against two unforgiving constraints: patient safety and time. Every implant, imaging system, and connected diagnostic tool must survive years of physical prototyping, bench testing, animal studies, and clinical trials before it ever reaches a patient. Digital twins i...
Read More...
Aug 04, 2026
EU Approves Datroway for First-Line Metastatic TNBC; FDA Broadens Pluvicto’s Reach with Approval in PSMA+ mHSPC; AbbVie Announces EU Authorization of RINVOQ for Severe Alopecia Areata; Novo Nordisk Announces Latest Developments from the ZEUS Phase III Trial; Replimune Secures Positive FDA Advisory Committee Vote for RP1 in Advanced Melanoma
Datroway Receives EU Approval for First-Line Metastatic TNBC Patients Ineligible for Immunotherapy AstraZeneca and Daiichi Sankyo have secured European Commission approval for Datroway (datopotamab deruxtecan) as a monotherapy for the first-line treatment of adults with unresectable or metastatic triple-negative...
Read More...
Aug 03, 2026
PROTACs: An Emerging Drug Modality with Multiple Oncology Approvals Expected in the Coming Years
Summary PROTACs represent a new modality that eliminates target proteins by leveraging the cell’s ubiquitin-proteasome system. Vepdegestrant (VEPPANU) became the first FDA-approved PROTAC therapy in May 2026 for the treatment of ER+/HER2- ESR1-mutated breast cancer, representing a significant milestone for t...
Read More...
Jul 31, 2026
Otsuka’s SIMTRIYO Approval Opens Up a Brand-New ADHD Drug Class
Summary FDA approved Otsuka’s SIMTRIYO (centanafadine) on July 24, 2026, for ADHD treatment in patients aged ≥6 years weighing at least 20 kg. First-in-class norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), introducing a novel triple-mechanism approach. Approval backed by four Phase 3 trial...
Read More...
Jul 30, 2026
SIO Urges NCCN to Add Cryoablation to Breast Cancer Guidelines Following ProSense® FDA Clearance; NIPRO CORPORATION Secures FDA 510(k) Clearance for ELISIO™-HX HDs in the US; Akido Unveils the First AI-Native Health System in the U.S.; MemorialCare Enhances Diagnostic Imaging with Hung Family-Funded 3T MRI Technology; Aqua Medical Treats First U.S. Type 2 Diabetes Patient at UNC Health with Investigational Endoscopic Therapy; NeoCast Delivers Robust Hematoma Resolution and Functional Recovery in Final EMBO-02 First-in-Human Results
ceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense® On 29 July 2026, the Society of Interventional Oncology (SIO) submitted a formal petition to the National Comprehensive Cancer Network (NCCN) seeking the inclusion of percut...
Read More...
Jul 29, 2026
Neurotechnology: Transforming the Future of Brain Health and Human–Machine Interaction
For most of medical history, the brain has been the one organ we could describe but barely touch. Today, that's changing fast. A new wave of devices, implants, and algorithms is learning to listen to the brain's electrical language, and, increasingly, to talk back to it. This convergence of neuroscience, engineerin...
Read More...
Jul 28, 2026
Ultomiris Phase III Trial Update Highlights Progress in Post-Transplant TMA; argenx Acquires Forte Biosciences; Otsuka’s SIMTRIYO Receives FDA Nod as a First-in-Class ADHD Treatment; Outlook Therapeutics Secures FDA Approval for LYTENAVA to Treat Wet AMD; Merck Reveals Future Access Strategy for Once-Monthly Oral HIV Prevention Therapy Alimatravir
Phase III Ultomiris Trial Reports Progress in Adults and Adolescents with HSCT-Related TMA Topline findings from the Phase III ALXN1210-TMA-313 trial indicated that Ultomiris (ravulizumab) did not meet the primary endpoint of event-free survival over 26 weeks versus placebo in adults and adolescents (12 years an...
Read More...
Jul 27, 2026
PD-1 Inhibitors: Which Companies Are Winning the Immunotherapy Race?
Summary The PD-1 inhibitors market is led by Merck’s KEYTRUDA and Bristol Myers Squibb’s OPDIVO, which together still dominate global revenue and remain the standard-bearers in the category. Challenger PD-1 drugs such as Sanofi/Regeneron’s LIBTAYO, GSK’s JEMPERLI, and Incyte’s ZYNYZ have carved out positions...
Read More...